Home
  2014.11.27.Thurs.
E-Journal
Online Submissions
Feed Back
Papers With
a High
Impact Factor
Links
Visiting Times:
    
Visiting Times
  of Today:
      
 Now Online:
      
 
New IF of World Journal of Gastroenterology for 2009 is 2.092.
 HTML      PDF

Tarantino G, Gentile A, Capone D, Basile V, Tarantino M, Di Minno MN, Cuocolo A, Conca P.Does protracted antiviral therapy impact on HCV-related liver cirrhosis progression?.
World J Gastroenterol 2007 September;13(36):4903-4908

Does protracted antiviral therapy impact on HCV-related liver cirrhosis progression?

Tarantino G, Gentile A, Capone D, Basile V, Tarantino M, Di Minno MN, Cuocolo A, Conca P.

Department of Clinical and Expermtal Medicine, Federico II University Medical School of Naples,Via S. Pansini, 5, Naples 80131, Italy. tarantin@unina.it

AIM: To study the outcomes of patients with compensated hepatitis C virus-related cirrhosis. METHODS: Twenty-four grade A5 and 11 grade A6 of Child-Pugh classification cirrhotic patients with active virus replication, treated for a mean period of 31.3 +/- 5.1 mo with moderate doses of interferon-alpha and ribavirin, were compared to a cohort of 36 patients with similar characteristics, without antiviral treatment. Salivary caffeine concentration, a liver test of microsomal function, was determined at the starting and thrice in course of therapy after a mean period of 11 +/- 1.6 mo, meanwhile the resistive index of splenic artery at ultra sound Doppler, an indirect index of portal hypertension, was only measured at the beginning and the end of study. RESULTS: Eight out of the 24 A5- (33.3%) and 5 out of the 11 A6- (45.45%) treated-cirrhotic patients showed a significant improvement in the total overnight salivary caffeine assessment. A reduction up to 20% of the resistive index of splenic artery was obtained in 3 out of the 8 A5- (37.5%) and in 2 out of the 5 A6- (40%) cirrhotic patients with an improved liver function, which showed a clear tendency to decrease at the end of therapy. The hepatitis C virus clearance was achieved in 3 out of the 24 (12.5%) A5- and 1 out of the 11 (0.091%) A6-patients after a median period of 8.5 mo combined therapy. In the cohort of non-treated cirrhotic patients, not only the considered parameters remained unchanged, but 3 patients (8.3%) had a worsening of the Child-Pugh score (P = 0.001). CONCLUSION: A prolonged antiviral therapy with moderate dosages of interferon-alpha and ribavirin shows a trend to stable liver function or to ameliorate the residual liver function, the entity of portal hypertension and the compensation status at acceptable costs.
 


Baishideng Publishing Group Co., Limited, Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road, Wan Chai, Hong Kong, China
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.